ReviewBMC neurology2026
Anti-mGluR encephalitis: case series and literature review.
Review in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Methotrexate-induced myelopathy: a great imitator of relapsed malignant lymphoma.BMC neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionAnti-metabotropic glutamate receptors (mGluR) encephalitis is a rare form of autoimmune encephalitis (AE) with a very limited number of documented cases.
objectiveTo report detailed characteristics of a case series of patients with anti-mGluR encephalitis and perform literature review of previously described cases.
methodsWe described clinical data from a case series of anti-mGluR patients, including clinical presentation, paraclinical findings and response to treatment. Moreover, we performed a literature review according to PRISMA to identify already described cases.
resultsIn our hospital we identified eight patients tested positive for anti-mGluR antibodies (1 for anti-mglur1, 1 for anti-mglur2 and 6 for anti-mglur2) either cerebrospinal fluid or serum. In most cases, brain magnetic resonance imaging (MRI) was unremarkable (at early stage) and most patients showed marked improvement after immunotherapy. Literature review allowed us to further identify 36 cases of anti-mGluR1 AE, 8 cases of anti-mGluR2 AE, 34 cases of anti-mGluR5 AE. Overall, 53(%), 13 (%) and 69(%) of patients with anti-mGluR1, anti-mGluR2 and anti-mGluR5, respectively, were male. The mean age of onset was respectively 51, 37 and 38. Patients with anti-mGLUR1 and anti-mGLur2 mainly manifested ataxia, while those with anti-mGLUR5 antibodies manifested psychiatric symptoms. In patients with anti-mGluR5 AE, associations with Hodgkin’s lymphoma (HL), other antibodies associated with AE and infectious triggers were frequent.
conclusionAnti-mGluR AE may present with heterogenous manifestations, according to the subtype of antibody. Early immunotherapy often improves outcomes, though some cases may relapse or develop cerebellar atrophy. Long-term follow-up is necessary, and underlying tumors—particularly HL in anti-mGluR5 AE—should be monitored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.